CD8A and metabolic dysfunction-associated steatohepatitis: Pfister et al. demonstrated through preclinical models of NASH-induced HCC that the increase of hepatic CD8+PD1+ T cells induced by immunotherapy impairs immune surveillance and did not lead to tumor regression [17].